This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Information on adverse event reporting can be found at the bottom of this page.
Our Oncology Portfolio
At Pfizer, we apply science and our global resources to bring therapies to people that may extend or help to improve their lives.
Over the past decade, we’ve taken bold new approaches to translate scientific research into effective medicines for people living with cancer. Today, our portfolio includes cancer medicines and biosimilars across multiple indications, including breast, genitourinary, blood and lung cancers.
approved oncology medicines and biosimilars1
therapeutic indications in different cancers1
people around the world treated with Pfizer Oncology products in 20211
In Northern Ireland, Lorviqua (lorlatinib) has a conditional marketing authorisation.
We believe nothing is more urgent, or more personal, than our goal to develop the next generation of potential cancer therapies.
We're proud to partner with organisations that share our purpose to deliver the right treatment for each patient, at the right time.
For over two decades, we have worked tirelessly in our pursuit to develop innovative and accessible treatments for those living with cancer.
In addition to manufacturing medicines, we're engaged in a number of initiatives that we hope will improve the lives of those impacted by cancer.
References:
1. Pfizer data on file.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021